Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors

Merck (NYSE:MRK) has performed well on the stock market this year. Since early January, the company's shares are up by about 15%, which compares favorably to the return provided by the pharmaceutical industry -- as measured by the SPDR S&P Pharmaceuticals Index -- which is up 10% year to date. The main reason behind Merck's performance has been none other than its blockbuster cancer medicine Keytruda. The company's top-selling product continues to spearhead its top-line growth, but there's something investors should appreciate: Merck's revenue isn't too reliant on Keytruda.